Regeneron Pharmaceuticals Stock Buy Hold or Sell Recommendation
| REGN Stock | USD 892.48 9.28 1.05% |
Given the investment horizon of 90 days and complete risk avoidance on your part, our recommendation regarding Regeneron Pharmaceuticals is 'Strong Sell'. Macroaxis provides Regeneron Pharmaceuticals buy-hold-or-sell recommendation only in the context of selected investment horizon and investor attitude towards risk assumed by holding REGN positions. The advice algorithm takes into account all of Regeneron Pharmaceuticals' available fundamental, technical, and predictive indicators you will find on this site. Key drivers impacting Regeneron Pharmaceuticals' buy or sell advice are summarized below:
Real Value 913.86 | Target Price 912.52 | Hype Value 891.75 | Market Value 892.48 | Naive Value 891.8 |
A buy or sell recommendation provided by Macroaxis is an automated directive regarding whether to purchase or sell Regeneron Pharmaceuticals given historical horizon and risk tolerance towards Regeneron Pharmaceuticals. When Macroaxis issues a 'buy' or 'sell' recommendation for Regeneron Pharmaceuticals, the advice is generated through an automated system that utilizes algorithms and statistical models.
Regeneron |
Execute Regeneron Pharmaceuticals Buy or Sell Advice
The Regeneron recommendation should be used to complement the buy-or-sell advice compiled from the current analysts' consensus on Regeneron Pharmaceuticals. Macroaxis does not own or have any residual interests in Regeneron Pharmaceuticals or other equities on which the buy-or-sell advice is provided. Please provide your input below to execute Regeneron Pharmaceuticals' advice using the current market data and latest reported fundamentals.
Time Horizon
Risk Tolerance
 |  |
Strong Sell
Market Performance | Very Weak | Details | |
Volatility | Very steady | Details | |
Hype Condition | Low key | Details | |
Current Valuation | Fairly Valued | Details | |
Odds Of Distress | Very Small | Details | |
Economic Sensitivity | Follows the market closely | Details | |
Investor Sentiment | Alarmed | Details | |
Analyst Consensus | Buy | Details | |
Financial Strenth (F Score) | Healthy | Details | |
Financial Leverage | Not Rated | Details | |
Reporting Quality (M-Score) | Unlikely Manipulator | Details |
Regeneron Pharmaceuticals Trading Alerts and Improvement Suggestions
| Regeneron Pharmaceuticals generated a negative expected return over the last 90 days | |
| Regeneron Pharmaceuticals is unlikely to experience financial distress in the next 2 years | |
| Over 89.0% of the company shares are owned by institutional investors | |
| Latest headline from finance.yahoo.com: Sanofi Q1 2024 Earnings Call Transcript |
Regeneron Pharmaceuticals Returns Distribution Density
The distribution of Regeneron Pharmaceuticals' historical returns is an attempt to chart the uncertainty of Regeneron Pharmaceuticals' future price movements. The chart of the probability distribution of Regeneron Pharmaceuticals daily returns describes the distribution of returns around its average expected value. We use Regeneron Pharmaceuticals price's Value At Risk and its Upside Potential as a relative measure of the distribution. The graph of the distribution of Regeneron Pharmaceuticals returns is essential to provide solid investment advice for Regeneron Pharmaceuticals.
| Mean Return | -0.1 | Value At Risk | -1.7 | Potential Upside | 1.59 | Standard Deviation | 0.91 |
Return Density |
| Distribution |
Investment risk management requires an estimate of the probability of extreme price changes. Therefore, the correct representation of the distribution of Regeneron Pharmaceuticals historical returns presented in an easy-to-digest graphical form helps investors and money managers understand the risk-reward trade-off of different investement strategies.
Regeneron Stock Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Regeneron Pharmaceuticals is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Regeneron Pharmaceuticals backward and forwards among themselves. Regeneron Pharmaceuticals' institutional investor refers to the entity that pools money to purchase Regeneron Pharmaceuticals' securities or originates loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Morgan Stanley - Brokerage Accounts | 2023-12-31 | 1.1 M | Wellington Management Company Llp | 2023-12-31 | 1.1 M | Norges Bank | 2023-12-31 | 1.1 M | Northern Trust Corp | 2023-12-31 | 1 M | Legal & General Group Plc | 2023-12-31 | 985.5 K | Bank Of New York Mellon Corp | 2023-12-31 | 948.6 K | American Century Companies Inc | 2023-12-31 | 931.3 K | Amundi | 2023-12-31 | 914.1 K | Bank Of America Corp | 2023-12-31 | 878.4 K | Fmr Inc | 2023-12-31 | 10.3 M | Vanguard Group Inc | 2023-12-31 | 8.8 M |
Regeneron Pharmaceuticals Cash Flow Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Change In Cash | 150.1M | 577M | 690.8M | 221.3M | (381.6M) | (362.5M) | |
| Free Cash Flow | 2.0B | 2.0B | 6.5B | 4.4B | 3.7B | 3.9B | |
| Depreciation | 210.3M | 235.9M | 286.2M | 341.4M | 421M | 442.1M | |
| Other Non Cash Items | (29.3M) | (135M) | 181.7M | 599.8M | 266.3M | 279.6M | |
| Capital Expenditures | 429.6M | 614.6M | 551.9M | 590.1M | 926.4M | 972.7M | |
| Net Income | 2.1B | 3.5B | 8.1B | 4.3B | 4.0B | 4.2B | |
| End Period Cash Flow | 1.6B | 2.2B | 2.9B | 3.1B | 2.7B | 2.9B | |
| Change To Inventory | (335.5M) | (529.4M) | (494.3M) | (696.5M) | (271.7M) | (258.1M) | |
| Investments | (1.6B) | 544M | (4.8B) | (1.9B) | (5.0B) | (4.7B) | |
| Change To Netincome | 314.2M | (895.1M) | (994M) | 676.5M | 608.9M | 639.3M |
Regeneron Pharmaceuticals Greeks
Most traded equities are subject to two types of risk - systematic (i.e., market) and unsystematic (i.e., nonmarket or company-specific) risk. Unsystematic risk is the risk that events specific to Regeneron Pharmaceuticals or Biotechnology sector will adversely affect the stock's price. This type of risk can be diversified away by owning several different stocks in different industries whose stock prices have shown a small correlation to each other. On the other hand, systematic risk is the risk that Regeneron Pharmaceuticals' price will be affected by overall stock market movements and cannot be diversified away. So, no matter how many positions you have, you cannot eliminate market risk. However, you can measure a Regeneron stock's historical response to market movements and buy it if you are comfortable with its volatility direction. Beta and standard deviation are two commonly used measures to help you make the right decision.
α | Alpha over NYSE Composite | -0.18 | |
β | Beta against NYSE Composite | 0.88 | |
σ | Overall volatility | 0.89 | |
Ir | Information ratio | -0.21 |
Regeneron Pharmaceuticals Volatility Alert
Regeneron Pharmaceuticals exhibits very low volatility with skewness of -0.1 and kurtosis of -0.39. Understanding different market volatility trends often help investors to time the market. Properly using volatility indicators enable traders to measure Regeneron Pharmaceuticals' stock risk against market volatility during both bullish and bearish trends. The higher level of volatility that comes with bear markets can directly impact Regeneron Pharmaceuticals' stock price while adding stress to investors as they watch their shares' value plummet. This usually forces investors to rebalance their portfolios by buying different financial instruments as prices fall.Regeneron Pharmaceuticals Implied Volatility
Regeneron Pharmaceuticals' implied volatility exposes the market's sentiment of Regeneron Pharmaceuticals stock's possible movements over time. However, it does not forecast the overall direction of its price. In a nutshell, if Regeneron Pharmaceuticals' implied volatility is high, the market thinks the stock has potential for high price swings in either direction. On the other hand, the low implied volatility suggests that Regeneron Pharmaceuticals stock will not fluctuate a lot when Regeneron Pharmaceuticals' options are near their expiration.
Regeneron Pharmaceuticals Fundamentals Vs Peers
Comparing Regeneron Pharmaceuticals' fundamentals to the average values of its peers is one of the most widely used and accepted methods of equity analyses. It helps to analyze Regeneron Pharmaceuticals' direct or indirect competition across all of the common fundamentals between Regeneron Pharmaceuticals and the related equities. This way, we can detect undervalued stocks with similar characteristics as Regeneron Pharmaceuticals or determine the stocks which would be an excellent addition to an existing portfolio. Peer analysis of Regeneron Pharmaceuticals' fundamental indicators could also be used in its relative valuation, which is a method of valuing Regeneron Pharmaceuticals by comparing valuation metrics with those of similar companies.
| Better Than Average | Worse Than Average | Compare Regeneron Pharmaceuticals to competition |
| Fundamentals | Regeneron Pharmaceuticals | Peer Average |
| Return On Equity | 0.16 | -0.31 |
| Return On Asset | 0.0849 | -0.14 |
| Profit Margin | 0.30 % | (1.27) % |
| Operating Margin | 0.29 % | (5.51) % |
| Current Valuation | 86.86 B | 16.62 B |
| Shares Outstanding | 107.94 M | 571.82 M |
| Shares Owned By Insiders | 1.69 % | 10.09 % |
| Shares Owned By Institutions | 88.91 % | 39.21 % |
| Number Of Shares Shorted | 1.39 M | 4.71 M |
| Price To Earning | 15.51 X | 28.72 X |
| Price To Book | 3.82 X | 9.51 X |
| Price To Sales | 7.57 X | 11.42 X |
| Revenue | 13.12 B | 9.43 B |
| Gross Profit | 7.02 B | 27.38 B |
| EBITDA | 4.05 B | 3.9 B |
| Net Income | 3.95 B | 570.98 M |
| Cash And Equivalents | 7.02 B | 2.7 B |
| Cash Per Share | 65.75 X | 5.01 X |
| Total Debt | 2.7 B | 5.32 B |
| Debt To Equity | 0.13 % | 48.70 % |
| Current Ratio | 5.36 X | 2.16 X |
| Book Value Per Share | 242.47 X | 1.93 K |
| Cash Flow From Operations | 4.59 B | 971.22 M |
| Short Ratio | 3.05 X | 4.00 X |
| Earnings Per Share | 34.80 X | 3.12 X |
| Price To Earnings To Growth | 1.46 X | 4.89 X |
| Target Price | 1051.33 | |
| Number Of Employees | 13.45 K | 18.84 K |
| Beta | 0.14 | -0.15 |
| Market Capitalization | 96.94 B | 19.03 B |
| Total Asset | 33.08 B | 29.47 B |
| Retained Earnings | 27.26 B | 9.33 B |
| Working Capital | 16.06 B | 1.48 B |
Note: Disposition of tradable shares by Andrew Murphy of Regeneron Pharmaceuticals at 962.87 subject to Rule 16b-3 [view details]
Regeneron Pharmaceuticals Market Momentum
Traders often use several daily momentume indicators to supplement a more traditional technical analysis when analyzing securities such as Regeneron . With many different options, investors must choose the best indicators for them and familiarize themselves with how they work. We suggest combining traditional momentum indicators with more near-term forms of technical analysis such as Accumulation Distribution or Daily Balance Of Power. With their quantitative nature, daily value technical indicators can also be incorporated into your automated trading systems.
About Regeneron Pharmaceuticals Buy or Sell Advice
When is the right time to buy or sell Regeneron Pharmaceuticals? Buying financial instruments such as Regeneron Stock isn't very hard. However, what challenging for most investors is doing it at the right time to beat the market. Proper market timing is something most people cannot do without sophisticated tools, which help to isolate the right opportunities. Macroaxis provides hands-on modules to deliver winning trades and diversify your portfolios on a daily basis. Most of our advising modules are very easy to use and apply.
Please read more on our stock advisor page.| 2021 | 2022 | 2023 | 2024 (projected) | Total Current Liabilities | 3.5B | 3.8B | 3.4B | 3.6B | Total Assets | 25.4B | 29.2B | 33.1B | 34.7B |
Use Investing Ideas to Build Portfolios
In addition to having Regeneron Pharmaceuticals in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Large Value Funds Thematic Idea Now
Large Value Funds
Funds or Etfs that invest in the undervalued stocks of large-sized companies. The Large Value Funds theme has 41 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Large Value Funds Theme or any other thematic opportunities.
| View All Next | Launch |
Check out Regeneron Pharmaceuticals Analyst Recommendation to compare Macroaxis Buy or Sell Recommendation with the current analyst consensus. To check ratings for multiple equity instruments, please use the Instant Ratings tool. To learn how to invest in Regeneron Stock, please use our How to Invest in Regeneron Pharmaceuticals guide.Note that the Regeneron Pharmaceuticals information on this page should be used as a complementary analysis to other Regeneron Pharmaceuticals' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Pattern Recognition module to use different Pattern Recognition models to time the market across multiple global exchanges.
Complementary Tools for Regeneron Stock analysis
When running Regeneron Pharmaceuticals' price analysis, check to measure Regeneron Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Regeneron Pharmaceuticals is operating at the current time. Most of Regeneron Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Regeneron Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Regeneron Pharmaceuticals' price. Additionally, you may evaluate how the addition of Regeneron Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
| Price Exposure Probability Analyze equity upside and downside potential for a given time horizon across multiple markets | |
| Global Correlations Find global opportunities by holding instruments from different markets | |
| Portfolio Dashboard Portfolio dashboard that provides centralized access to all your investments | |
| Crypto Correlations Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins | |
| Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities | |
| Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Bollinger Bands Use Bollinger Bands indicator to analyze target price for a given investing horizon | |
| Portfolio Center All portfolio management and optimization tools to improve performance of your portfolios | |
| My Watchlist Analysis Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like | |
| Sync Your Broker Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors. |
Is Regeneron Pharmaceuticals' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Regeneron Pharmaceuticals. If investors know Regeneron will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Regeneron Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.03) | Earnings Share 34.8 | Revenue Per Share 122.935 | Quarterly Revenue Growth 0.006 | Return On Assets 0.0849 |
The market value of Regeneron Pharmaceuticals is measured differently than its book value, which is the value of Regeneron that is recorded on the company's balance sheet. Investors also form their own opinion of Regeneron Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Regeneron Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Regeneron Pharmaceuticals' market value can be influenced by many factors that don't directly affect Regeneron Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Regeneron Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Regeneron Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Regeneron Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.